MEET YOUR NEW AI CLINICAL ASSISTANT /// GET EARLY ACCESS
If you’re wondering how Tempus’s sequencing services can help your project move forward, consider the experiences of these four organizations, who partnered with Tempus for prospective sequencing for clinical trials, retrospective sequencing and analyses, companion diagnostic development, and sponsored testing.
Tempus has recently announced the PMA approval for xT CDx, our solid tumor CDx and 648 gene panel.
In this webinar, you will hear how the Tempus platform can support development of new therapies by combining real-world data, next-generation sequencing, and artificial-intelligence to advance precision oncology. Our regulatory and scientific experts will provide an overview of the pathways for diagnostics and share best practices for biopharma and biotech sponsors to consider in clinical trial design and the development of companion diagnostics.
The Tempus TIME program provided Aadi access to a network of providers and patients to accelerate enrollment for its PRECISION 1 TSC1/TSC2 phase 2 clinical trial. Read on to learn how the TIME program decreased time to enroll with the just-in-time activation of ~10 business days.
Read more
Learn how AstraZeneca employs multimodal data to increase the probability of technical success of all Phase 3 oncology studies.
Watch replay